Results 171 to 180 of about 927,791 (328)

Clinical Microbiology in the Year 2025

open access: green, 2002
W. Michael Dunne   +2 more
openalex   +1 more source

Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction Therapy

open access: yesAmerican Journal of Hematology, EarlyView.
Early cardiac biomarker monitoring in AML induction therapy showed significantly higher hsTnT levels after daunorubicin 90 mg/m2 compared with 60 mg/m2, indicating a dose‐dependent early myocardial effect. ABSTRACT Anthracyclines are an essential component of induction therapy for acute myeloid leukemia (AML), but their optimal dosing and the ...
Stefan Markus Dendorfer   +44 more
wiley   +1 more source

Reaffirming DEI as a central value of JCM

open access: yesJournal of Clinical Microbiology
Romney M. Humphries, Alexander J. McAdam
doaj   +1 more source

Acute Exercise Challenge and Airway Dynamics in Youth With Sickle Cell Anemia: A Multicenter Study

open access: yesAmerican Journal of Hematology, EarlyView.
Changes in airway dynamics in children with sickle cell anemia after maximal cardiopulmonary exercise testing and a controlled intensity interval excercise challenge. ABSTRACT Sickle cell anemia (SCA) leads to reduced physical functioning and cardiopulmonary fitness. Prior studies suggest that airway hyperresponsiveness to bronchoprovocation testing is
Robyn T. Cohen   +9 more
wiley   +1 more source

Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower‐Risk Myelodysplastic Syndromes (LR‐MDS) in the COMMANDS Study

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT The COMMANDS trial established luspatercept as a first‐line treatment for anemia in transfusion‐dependent lower‐risk (LR) myelodysplastic syndromes (MDS). Here we report red blood cell (RBC) transfusion response analysis based on somatic mutations profile and disease risk for patients treated with luspatercept or epoetin alfa in the COMMANDS ...
Rami S. Komrokji   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy